GENinCode (GENI) Share Price, News & Analysis

Company Overview

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide. GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U. GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.

Key Stats

• Today's Range: 1.60 to 2
• 50-Day Range: 1.50 to 2.50
• 52-Week Range: 1 to 8.50
• Volume: 374,681 shs
• Average Volume: 623,244 shs
• Market Capitalization: £3.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GENI Stock Analysis - Frequently Asked Questions

How have GENI shares performed this year?

GENinCode's stock was trading at GBX 3.89 at the start of the year. Since then, GENI shares have decreased by 53.0% and is now trading at GBX 1.83.

How were GENinCode's earnings last quarter?

GENinCode Plc (LON:GENI) issued its quarterly earnings data on Wednesday, June, 4th. The company reported ($2.53) earnings per share for the quarter. GENinCode had a negative trailing twelve-month return on equity of 289.74% and a negative net margin of 228.70%.

How do I buy shares of GENinCode?

Shares of GENI stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of GENinCode own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GENinCode investors own include QUALCOMM (QCOM), Sound Energy (SOU), Zura Bio (ZURA), Capital One Financial (COF), Lincoln National (LNC), Ovid Therapeutics (OVID) and Plug Power (PLUG).

Company Calendar

• Last Earnings: 6/04/2025
• Today: 8/02/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: Entertainment
• Current Symbol: LON:GENI
• CIK: N/A
• Web: www.genincode.com
• Phone: 44 1865 955 847
• Fax: N/A
• Employees: 2,300
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX (3.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£6.10 million
• Net Margins: -228.70%
• Pretax Margin: N/A
• Return on Equity: -289.74%
• Return on Assets: -63.99%

Debt

• Debt-to-Equity Ratio: 9.28
• Current Ratio: 2.60
• Quick Ratio: 15.89

Sales & Book Value

• Annual Sales: £2.67 million
• Price / Sales: 1.22
• Cash Flow: GBX 2.19 per share
• Price / Cash Flow: 0.83
• Book Value: GBX 1.63 per share
• Price / Book: 1.12

Miscellaneous

• Outstanding Shares: 177,407,519
• Free Float: N/A
• Market Cap: £3.24 million
• Optionable: Not Optionable
• Beta: 0.66